A

ABL Bio Inc
KOSDAQ:298380

Watchlist Manager
ABL Bio Inc
KOSDAQ:298380
Watchlist
Price: 34 450 KRW 2.23% Market Closed
Market Cap: 1.7T KRW
ABL Bio Inc
/
Income Statement
/
Income from Continuing Operations

ABL Bio Inc
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

ABL Bio Inc
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
A
ABL Bio Inc
KOSDAQ:298380
Income from Continuing Operations
-₩55.5B
CAGR 3-Years
-8%
CAGR 5-Years
-8%
CAGR 10-Years
N/A
Celltrion Inc
KRX:068270
Income from Continuing Operations
₩418.9B
CAGR 3-Years
-11%
CAGR 5-Years
7%
CAGR 10-Years
14%
SK Bioscience Co Ltd
KRX:302440
Income from Continuing Operations
-₩50.1B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
Hugel Inc
KOSDAQ:145020
Income from Continuing Operations
₩143.1B
CAGR 3-Years
34%
CAGR 5-Years
23%
CAGR 10-Years
N/A
P
PharmaResearch Co Ltd
KOSDAQ:214450
Income from Continuing Operations
₩88.9B
CAGR 3-Years
24%
CAGR 5-Years
43%
CAGR 10-Years
26%
Alteogen Inc
KOSDAQ:196170
Income from Continuing Operations
₩60.7B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
52%

ABL Bio Inc
Glance View

Market Cap
1.7T KRW
Industry
Biotechnology

ABL Bio, Inc. engages in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2018-12-19. The major products include anti-angiogenesis antibodies anti-tumor targeting antibodies, T cell engager bispecific antibodies (TCEs), dual immune cell targeting bispecific antibodies (DICs), novel immune cell targeting antibodies (NICs), brain disease dual antibodies, antibody-drug conjugates (ADCs) , among others.

Intrinsic Value
9 630.52 KRW
Overvaluation 72%
Intrinsic Value
Price
A
What is Intrinsic Value?

See Also

What is ABL Bio Inc's Income from Continuing Operations?
Income from Continuing Operations
-55.5B KRW

Based on the financial report for Dec 31, 2024, ABL Bio Inc's Income from Continuing Operations amounts to -55.5B KRW.

What is ABL Bio Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-8%

Over the last year, the Income from Continuing Operations growth was -1 998%. The average annual Income from Continuing Operations growth rates for ABL Bio Inc have been -8% over the past three years , -8% over the past five years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 242,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.